Skip to main content
. 2021 Sep 13;2(6):421–425. doi: 10.3168/jdsc.2021-0142

Figure 3.

Figure 3

(A) Mean (±SEM) circulating 13,14-dihydro-15-keto-prostaglandin F2α (PGFM) −2 to 6 h relative to treatment (0 h) with dinoprost tromethamine intramuscularly (IM; n = 6) or subcutaneously (SC; n = 6). (B) Mean (±SEM) circulating progesterone (P4) −2 to 24 h relative to treatment (0 h) with dinoprost tromethamine IM (n = 6) or SC (n = 5). Cow 7292 (SC treatment) was removed from the circulating P4 analysis due to failure to undergo complete luteolysis by 56 h (P4 <0.5 ng/mL) with P4 of 1.46 ng/mL.